High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant

M. De Lima, K. Van Besien, J. Gajewski, I. Khouri, B. Andersson, M. Korbling, R. Champlin, S. Giralt

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients with acute leukemias relapsing within 1 year of an allogeneic BMT have a poor prognosis. We studied the use of melphalan 180 mg/m2 followed by allogeneic peripheral blood stem cells (PBSC) as salvage treatment for patients relapsing after related (n = 7) or matched unrelated transplants (n = 3). Diagnoses were AML (n = 4), ALL (n = 3), biphenotypic acute leukemia (n = 2) and CML in blast crisis (n = 1). Eight patients were beyond first relapse and none were in remission. The median time from previous transplant to relapse was 146 days (range 66-206). The melphalan dose was 90 mg/m2 intravenously on days -4 and -3 with PBSC infusion on day 0. GVHD prophylaxis consisted of cyclosporine and methylprednisolone. The median time to an absolute neutrophil count > 0.5 x 109/l and to a platelet count > 20 x 109/l was 11 and 13 days, respectively. All engrafting patients (n = 8) had 100% donor cells. Two patients died before day 30, but no other grade 3 or 4 toxicity occurred. Acute GVHD grades II-III occurred in two subjects, and chronic GVHD in four. Seven patients achieved CR, but relapsed at a median of 116 days (range 56-614). Leukemia was the cause of death in eight patients. Median survival was 149 days (range 6-614). This treatment produced responses in the majority of this poor prognosis group. However, durable remissions were not observed, and new treatments to consolidate the responses achieved in this setting are needed. This regimen could be considered for shortterm disease control to facilitate donor lymphocyte infusion-based immunotherapy or other measures to prevent disease recurrence.

Original languageEnglish (US)
Pages (from-to)333-338
Number of pages6
JournalBone Marrow Transplantation
Volume26
Issue number3
StatePublished - 2000
Externally publishedYes

Fingerprint

Peripheral Blood Stem Cell Transplantation
Melphalan
Transplants
Recurrence
Therapeutics
Leukemia
Biphenotypic Acute Leukemia
Tissue Donors
Blast Crisis
Salvage Therapy
Methylprednisolone
Platelet Count
Immunotherapy
Cyclosporine
Cause of Death
Neutrophils
Lymphocytes
Survival

Keywords

  • Acute leukemias
  • BMT
  • Melphalan
  • Relapse

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

De Lima, M., Van Besien, K., Gajewski, J., Khouri, I., Andersson, B., Korbling, M., ... Giralt, S. (2000). High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplantation, 26(3), 333-338.

High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. / De Lima, M.; Van Besien, K.; Gajewski, J.; Khouri, I.; Andersson, B.; Korbling, M.; Champlin, R.; Giralt, S.

In: Bone Marrow Transplantation, Vol. 26, No. 3, 2000, p. 333-338.

Research output: Contribution to journalArticle

De Lima, M, Van Besien, K, Gajewski, J, Khouri, I, Andersson, B, Korbling, M, Champlin, R & Giralt, S 2000, 'High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant', Bone Marrow Transplantation, vol. 26, no. 3, pp. 333-338.
De Lima, M. ; Van Besien, K. ; Gajewski, J. ; Khouri, I. ; Andersson, B. ; Korbling, M. ; Champlin, R. ; Giralt, S. / High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. In: Bone Marrow Transplantation. 2000 ; Vol. 26, No. 3. pp. 333-338.
@article{d984180bcfa649858dcabe56304fb263,
title = "High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant",
abstract = "Patients with acute leukemias relapsing within 1 year of an allogeneic BMT have a poor prognosis. We studied the use of melphalan 180 mg/m2 followed by allogeneic peripheral blood stem cells (PBSC) as salvage treatment for patients relapsing after related (n = 7) or matched unrelated transplants (n = 3). Diagnoses were AML (n = 4), ALL (n = 3), biphenotypic acute leukemia (n = 2) and CML in blast crisis (n = 1). Eight patients were beyond first relapse and none were in remission. The median time from previous transplant to relapse was 146 days (range 66-206). The melphalan dose was 90 mg/m2 intravenously on days -4 and -3 with PBSC infusion on day 0. GVHD prophylaxis consisted of cyclosporine and methylprednisolone. The median time to an absolute neutrophil count > 0.5 x 109/l and to a platelet count > 20 x 109/l was 11 and 13 days, respectively. All engrafting patients (n = 8) had 100{\%} donor cells. Two patients died before day 30, but no other grade 3 or 4 toxicity occurred. Acute GVHD grades II-III occurred in two subjects, and chronic GVHD in four. Seven patients achieved CR, but relapsed at a median of 116 days (range 56-614). Leukemia was the cause of death in eight patients. Median survival was 149 days (range 6-614). This treatment produced responses in the majority of this poor prognosis group. However, durable remissions were not observed, and new treatments to consolidate the responses achieved in this setting are needed. This regimen could be considered for shortterm disease control to facilitate donor lymphocyte infusion-based immunotherapy or other measures to prevent disease recurrence.",
keywords = "Acute leukemias, BMT, Melphalan, Relapse",
author = "{De Lima}, M. and {Van Besien}, K. and J. Gajewski and I. Khouri and B. Andersson and M. Korbling and R. Champlin and S. Giralt",
year = "2000",
language = "English (US)",
volume = "26",
pages = "333--338",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant

AU - De Lima, M.

AU - Van Besien, K.

AU - Gajewski, J.

AU - Khouri, I.

AU - Andersson, B.

AU - Korbling, M.

AU - Champlin, R.

AU - Giralt, S.

PY - 2000

Y1 - 2000

N2 - Patients with acute leukemias relapsing within 1 year of an allogeneic BMT have a poor prognosis. We studied the use of melphalan 180 mg/m2 followed by allogeneic peripheral blood stem cells (PBSC) as salvage treatment for patients relapsing after related (n = 7) or matched unrelated transplants (n = 3). Diagnoses were AML (n = 4), ALL (n = 3), biphenotypic acute leukemia (n = 2) and CML in blast crisis (n = 1). Eight patients were beyond first relapse and none were in remission. The median time from previous transplant to relapse was 146 days (range 66-206). The melphalan dose was 90 mg/m2 intravenously on days -4 and -3 with PBSC infusion on day 0. GVHD prophylaxis consisted of cyclosporine and methylprednisolone. The median time to an absolute neutrophil count > 0.5 x 109/l and to a platelet count > 20 x 109/l was 11 and 13 days, respectively. All engrafting patients (n = 8) had 100% donor cells. Two patients died before day 30, but no other grade 3 or 4 toxicity occurred. Acute GVHD grades II-III occurred in two subjects, and chronic GVHD in four. Seven patients achieved CR, but relapsed at a median of 116 days (range 56-614). Leukemia was the cause of death in eight patients. Median survival was 149 days (range 6-614). This treatment produced responses in the majority of this poor prognosis group. However, durable remissions were not observed, and new treatments to consolidate the responses achieved in this setting are needed. This regimen could be considered for shortterm disease control to facilitate donor lymphocyte infusion-based immunotherapy or other measures to prevent disease recurrence.

AB - Patients with acute leukemias relapsing within 1 year of an allogeneic BMT have a poor prognosis. We studied the use of melphalan 180 mg/m2 followed by allogeneic peripheral blood stem cells (PBSC) as salvage treatment for patients relapsing after related (n = 7) or matched unrelated transplants (n = 3). Diagnoses were AML (n = 4), ALL (n = 3), biphenotypic acute leukemia (n = 2) and CML in blast crisis (n = 1). Eight patients were beyond first relapse and none were in remission. The median time from previous transplant to relapse was 146 days (range 66-206). The melphalan dose was 90 mg/m2 intravenously on days -4 and -3 with PBSC infusion on day 0. GVHD prophylaxis consisted of cyclosporine and methylprednisolone. The median time to an absolute neutrophil count > 0.5 x 109/l and to a platelet count > 20 x 109/l was 11 and 13 days, respectively. All engrafting patients (n = 8) had 100% donor cells. Two patients died before day 30, but no other grade 3 or 4 toxicity occurred. Acute GVHD grades II-III occurred in two subjects, and chronic GVHD in four. Seven patients achieved CR, but relapsed at a median of 116 days (range 56-614). Leukemia was the cause of death in eight patients. Median survival was 149 days (range 6-614). This treatment produced responses in the majority of this poor prognosis group. However, durable remissions were not observed, and new treatments to consolidate the responses achieved in this setting are needed. This regimen could be considered for shortterm disease control to facilitate donor lymphocyte infusion-based immunotherapy or other measures to prevent disease recurrence.

KW - Acute leukemias

KW - BMT

KW - Melphalan

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=0033853782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033853782&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 333

EP - 338

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -